5:57 PM
 | 
Jan 24, 2013
 |  BC Extra  |  Company News

Meda's Dymista approved for allergic rhinitis

Meda AB (SSE:MEDAA) said its Dymista azelastine/fluticasone was approved under the EU's decentralized procedure to treat seasonal and perennial allergic rhinitis. Germany...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >